Abstract Perturbations of transforming growth factorbeta (TGF-b) signaling are pivotal to tumorigenesis and tumor progression through their effects on cell proliferation and cell invasion. This study aims to evaluate the association of TGF-bRII and pSmad2 protein expressions in breast tissue with clinicopathological factors and prognosis of breast cancer. Expression of the TGF-bRII and pSmad2 proteins was assessed in breast tissue of 1,045 breast cancer cases in the Shanghai Breast Cancer Study using a double immunofluorescence staining method, which was validated with standard single immunostains. TGF-bRII expression intensity was positively associated with younger age at diagnosis (P = 0.03), pre-menopausal status (P = 0.03), and lower TNM stage (P = 0.04). Cytoplasmic predominant expression pattern of TGF-bRII was associated with older age at diagnosis (P = 0.04) and invasive histological type (P = 0.03). Increased pSmad2 expression was associated with higher breast cancer grade (P \ 0.01). Higher pSmad2 expression [HR (95 % CI):1.48 (1.07-2.04), P = 0.02] and cytoplasmic predominant TGF-bRII expression [HR (95 % CI): 1.80 (1.08-3.00), P = 0.02] were significantly associated with reduced cancer-free survival. Our data suggest that TGF-bRII and pSmad2 expressions are associated with certain clinical and pathologic features of breast cancer. A cytoplasmic predominant TGF-bRII expression pattern and a higher pSmad2 expression were associated with decreased breast cancer survival. Our study provides additional evidence to support the important role of TGF-b signaling in breast cancer prognosis. 
Introduction
Perturbations of transforming growth factor-beta (TGF-b) signaling are central to tumorigenesis and tumor progression via their effects on cell proliferation and cell invasion [1] . The physiological consequences of TGF-b signaling are highly contextual with different or even opposite TGFb functions in cancerous and normal cells [2] . TGF-b family members signal through a heteromeric complex of transmembrane serine/threonine kinases, the type I and II receptors (TGF-bRI and TGF-bRII), which subsequently phosphorylate receptor-regulated Smad proteins (RSmads). R-Smads usually translocate to the nucleus together with the common mediator, Smad4, where they regulate gene transcription by binding to the promoter of target genes [3] [4] [5] [6] [7] [8] . Loss of TGF-b responsiveness frequently occurs at the level of TGF-bRII in many tumors, including breast cancer, colon cancer, and glioma [9] [10] [11] [12] . Smad2 is a major receptor-activated Smad downstream of TGF-b signaling. Phosphorylated Smad2 (pSmad2) is translocated into the nucleus to modulate the transcription of target genes involved in many cell functions [13] [14] [15] [16] [17] [18] . Our previous data indicated that high circulating levels of TGF-b1 are associated with worse survival independent of disease stage [19] , implying that TGF-b signaling may play an important role in breast cancer prognosis. However, no large studies have examined TGF-b signaling protein expression in both breast tumor and adjacent normal tissues [20] . In this study, we evaluated the correlation of TGFbRII and pSmad2 protein expression in 1,045 breast cancer cases with clinicopathological factors in human breast cancer tissue and prognosis of breast cancer from the Shanghai Breast Cancer Study.
Materials and methods

Study populations
The study population is from the second phase of the Shanghai Breast Cancer Study (SBCS-II), a populationbased case-control study being conducted in Shanghai, China [21] [22] [23] . Briefly, breast cancer cases were identified via the Shanghai Cancer Registry. Recruitment occurred between April 2002 and February 2005. Cancer diagnoses were reviewed and confirmed by two senior pathologists. A structured questionnaire was used to elicit detailed information on demographic factors for breast cancer. Trained interviewers measured all participants for weight, height, and circumferences of the waist and hips. All interviews were tape-recorded and reviewed by the field supervisor and quality control staff. The study was approved by the institutional review boards at all participating institutes, and all participants provided written, informed consent before participating in the study.
Clinicopathological data
Pathological slides for 1,045 cases were available for this study. The slides were collected from the diagnosis hospitals according to a standard protocol. Clinical information collected included cancer stage, tumor ERa and progesterone receptor (PR) status, and primary treatments. The HER2 status of cancer cases was evaluated previously by a centralized laboratory [23] . The diagnoses and clinicopathological data were confirmed by a combination of medical chart review and a centralized review of pathology slides. The histological types of breast cancer were confirmed according to the criteria of the World Health Organization classification [24] by the research pathologist (Su) . The histological grade of all cancer slides was determined using the Nottingham histological grading system.
Double-label fluorescent immunohistochemistry staining for TGF-bRII and pSmad2
Pathological sections of breast cancer samples were deparaffinized, and a sequential double immunofluorescence staining was performed using a Dako automated immunostainer (Dako Colorado, Inc., USA). In brief, the slides were put in citrate buffer (pH6, ZyMed, Cat# 00-5000), heated with a programmed pressure cooker (PickCell Laboratories B.V., Amsterdam, the Netherlands) for 2 h for antigen retrieval. After blocking steps with 3 % H 2 O 2 , 5 % normal goat serum, biotin solution, and avidin D solution (Vector, Cat# SP-2001), the slides were incubated with polyclonal rabbit antibody anti-TGF-bRII (Spring, Cat# E11244, 1:100) overnight at 4°C; biotin conjugated goat anti-rabbit (Vector, Cat# BA-1000, 1:300) for 30 min at 37°C; and streptavidin-Cy3 (Zymed, Cat# 43-8315, 1:100) for 15 min at 37°C. The slides were then incubated with polyclonal rabbit antibody anti-pSmad2 (Ser465/467) (Cell Signaling, Cat# 9510, 1:200) for 30 min at 37°C; biotin conjugated goat anti-rabbit for 30 min at 37°C; and streptavidin-FITC (Zymed, Cat# 43-8311, 1:100) for 30 min at 37°C. Slides were washed thoroughly, the coverslip was mounted with ProLong Gold antifade reagent with DAPI (Invitrogen, Cat# P36935), and slides were stored in the dark at 4°C. The double immunofluorescence staining protocol was validated by comparing it with a single standard staining method by the DAKO Envision TM kit (DAKO, Cat#K4011) using the control slides freshly cut from a lab-constructed tissue microarray (TMA) block which included one placenta tissue and three breast cancer tissues with tumor grades 1, 2, and 3 ( Fig. 1) . The TMA slides were also used as quality controls. Each batch of staining samples included two TMA slides as positive and negative controls. Before formal staining of the study samples, four TMA blocks including 182 valid cases of breast cancer made by our centralized laboratory were stained as a training set. Consistent staining results were observed with our system by comparing built-in control tissues and cell lines ( Supplementary Fig. 1a) .
TGF-bRII and pSmad2 were semi-quantified using a modified four-scale Allred Scoring System [25] in which the proportion of positive cells and staining intensity are taken into account: 0 (negative), no positive staining or less than 1/3 cells with weak fluorescent signal which is difficult to be identified under 9100 field (A-score B4); 1 (weak positive), 1/3-2/3 cells with weak fluorescent signal (A-score 5); 2 (moderate positive), more than 1/3 cells with moderate fluorescent signal which is easily identified under 9100 field or less than 2/3 cells with strong fluorescent signal (A-score 6-7); and 3 (strong positive), more than 2/3 cells with strong fluorescent signal (Ascore 8) (Supplementary Fig. 1b) . The staining pattern of TGF-bRII was classified into two groups: (1) membranous predominant as beehive-like appearance and (2) cytoplasmic or membranous cytoplasmic as cloudy appearance in the cells (Supplementary Fig. 1c ). The analysis was carried out independently by two observers (Su and Qiu), and the samples were scored blinded with respect to clinical patient data. All the slides with inconsistent results were jointly evaluated again by the two investigators, and a consensus score was used.
Statistical analysis
Chi-square test and ANOVA were used in the analysis for differences of characteristics and clinicopathological parameters among TGF-bRII and pSmad2 expressions. Fisher's exact test was used for the data of histological type because histological data were sparse. The primary outcome for this study was disease-free survival (DFS). For the DFS analysis, follow-up time was calculated as the number of days between the date of cancer diagnosis and disease recurrence or date of last survey for women who did not have disease recurrence or died of breast cancer. For women who died of breast cancer but were missing information on disease recurrence, we imputed the date for recurrence on the basis of the tumor-node-metastasis (TNM) stage-specific recurrence rate estimated for the current study. Multivariate Cox proportional hazards models were employed to evaluate the expressions of TGF-bRII and pSmad2 in association with breast cancer survival after adjusting for age at diagnosis, BMI, tumor size, grade, TNM stage, ER/ PR status, radiotherapy, chemotherapy, and tamoxifen treatment. Adjusted survival curves, based on a stratified Cox regression model, were applied to compare the breast cancer survival rate among breast cancer patients with different TGF-bRII and pSmad2 expression [26] . All the tests were performed using SAS (version 9.3; SAS Institute, Inc., Cary, North Carolina). The significance levels were set at P \ 0.05 and based on two-sided probability. Table 1 presents the characteristics of study participants. In this study, 1,045 breast cancer patients were included. The mean age was 51.4 years. There were 2.4 % breast cancer patients diagnosed at stage 0, 31.9 % at stage I, 32.9 % at stage IIa, 21.6 % at stage IIb, 10.5 % at stage III, and 0.7 % at stage IV. All patients received surgical treatment (100 %) and a vast majority received chemotherapy (94.4 %). Radiotherapy was given to 32.1 % of patients, whereas 54.2 % received tamoxifen therapy. TNM stage (P \ 0.01), histological grade (P \ 0.01), tumor size (P \ 0.01), PR status (P = 0.05), and radiotherapy (P \ 0.01) were significantly associated with DFS. Positive TGF-bRII expression was associated with younger age at diagnosis (P = 0.03), pre-menopausal status (P = 0.03), positive PR status (P = 0.03), and lower TNM stage (P = 0.04) ( Table 2 ). The cytoplasmic predominant expression pattern of TGF-bRII was associated with older age at diagnosis (P = 0.04) and invasive histological type (P = 0.03). TGF-bRII protein expression was unrelated to other prognostic factors, such as family history of breast cancer, tumor size, histological grade, ER status, HER2 status, and molecular type. pSmad2 expression was positively associated with higher breast cancer grade (P \ 0.01) but unrelated to ER, PR, and HER2 expression and other clinicopathological factors (Table 2) . Positive TGF-bRII expression (score 2-3) in breast cancer and adjacent normal breast epithelium were 88.2 and 97.0 %, respectively. TGF-bRII protein exhibited both cytoplasmic and membranous immunostaining patterns. Strong Positive TGF-bRII expression was more frequently observed in adjacent normal breast epithelium and early-stage breast cancer tissue (in situ carcinoma) than in invasive breast cancer tissue (P \ 0.01) (Table 3, Fig. 2) . The cytoplasmic predominant expression pattern of TGF-bRII was more frequently observed in breast cancer than in adjacent normal breast epithelium on the same pathological section (P \ 0.01). A total of 17.6 % of the adjacent normal breast epithelium and 84.8 % of the invasive breast carcinomas had a cytoplasmic expression pattern. Adjacent normal breast epithelium had stronger TGF-bRII expression intensity than that of the invasive breast carcinomas (70.7 vs. 44.1 %, score 3) (Table 3 ). pSmad2 expression was restricted to the nucleus. pSmad2 expression intensity was stronger in adjacent normal breast epithelium, in situ carcinoma, and in situ carcinoma tissue component within invasive breast carcinoma than in invasive breast carcinoma tissue (P \ 0.01) ( Table 3 and Fig. 2) . The correlation between pSmad2 intensity and TGF-b RII intensity is low (kappa = 0.12).
Results
Five-year DFS in patients expressing high pSmad2 was 80 % compared with 86 % in low (0-2) pSmad2 patients. Higher pSmad2 expression was significantly associated with lower DFS of breast cancer [HR (95 % CI):1.48 (1.07-2.04), P = 0.02, Table 4 and Fig. 3 ] adjusted for age at diagnosis and BMI. Further adjustment of tumor characteristics and therapy did not significantly change the HR estimate for breast cancer survival with pSmad2 intensity. The association of pSmad2 intensity with breast cancer survival was more pronounced in the ER-positive patients (Table 4) . Five-year cancer-free survival in patients expressing cytoplasmic predominant TGF-bRII was 82 % compared with 90 % in membranous predominant TGFbRII expression. Cytoplasmic predominant TGF-bRII was significantly associated with cancer-free survival of breast cancer [HR (95 % CI):1.80 (1.08-3.00), P = 0.02, Table 4 and Fig. 3] . However, the association of TGF-bRII pattern with breast cancer survival was borderline significant after adjusting for tumor characteristics and cancer therapy. The association of TGF-bRII pattern with breast cancer survival was not modified by ER status (Table 4) .
Five-year overall survival rate in patients expressing cytoplasmic predominant TGF-bRII was 86 % compared to 92 % (P = 0.03) in membranous predominant TGF-bRII expression. Five-year overall survival rate in patients expressing high pSmad2 was 84 % compared with 89 % in low pSmad2 expression patients (P = 0.01) (data not shown in table). 
Discussion
In this study, we found that breast cancer tissues had a lower TGF-bRII protein expression, a cytoplasmic predominant TGF-bRII expression pattern, and a higher pSmad2 expression compared to adjacent normal breast epithelium. Lower TGF-bRII protein expression, a cytoplasmic predominant TGF-bRII expression pattern, and a higher pSmad2 expression were associated with a decreased DFS. These results indicate that loss of TGFbRII expression in the membranes and translocation of TGF-bRII to cytoplasm, which may lead to increasing TGF-b downstream signaling by activating Smad2, was related to prognosis of breast cancers. It has been reported that TGF-bRII was only detected in the cytoplasm in breast cancer MCF7 cells and predominantly presented in MDA-MB-231 cells [27] . Translocation of TGF-bRII to cytoplasm may be a potential mechanism for loss of TGF-bmediated autocrine growth control and tumorigenicity in human breast cancer cells [27] . TGF-b acts as a tumor suppressor in normal epithelia by inhibiting cell proliferation and inducing apoptosis, but it accelerates progression of established cancers by autocrine and paracrine mechanisms [28, 29] . In transformed cells, signaling of TGF-b loses its tumor-suppressor effects and begins to function as a cancer-promoting agent that synergizes with transforming oncogenes [30] .
For the association between TGF-bRII/pSmad2 expression and clinicopathological factors, we found that loss of TGF-bRII expression occurs more frequently in patients with older age at diagnosis, post-menopausal status, negative PR status, and higher TNM stage. Cytoplasmic predominant TGF-bRII expression is associated with older age at diagnosis and invasive histological type. Higher pSmad2 expression is associated with higher tumor grade. Buck et al. [31] reported that TGF-bRII expression was correlated with a reduced overall survival in ER-negative patients. In our study, TGF-bRII expression was not associated with breast cancer survival. However, cytoplasmic predominant TGF-bRII expression and higher pSmad2 expression were associated with a statistically significant reduced cancer-free survival. Loss of TGF-bRII expression and increased pSmad2 were inversely and significantly associated with breast cancer DFS even after adjusting for known clinical predictors. These data indicate that increased pSmad2, cytoplasmic predominant TGFbRII expression, and reduced TGF-bRII may be independent predictors for poor prognosis of breast cancer.
In a study conducted among 178 breast biopsies, Gobbi et al. [32] observed a significant inverse correlation between loss of TGF-bRII expression and tumor grade within both ductal carcinoma in situ and invasive mammary carcinomas. Two studies using TMA have evaluated the association of TGF-bRII and pSmad2 expressions with breast cancer pathological factors and outcome. In a study conducted among 324 Brazilian breast cancer cases, Paiva et al. [33] showed that TGF-bRII positivity was associated with increased DFS in HER2-negative patients. However, no significant association between TGF-bRII and tumor stage was found [33] . A population-based, case-control study conducted in 842 Polish women found that TGF-bRII and pSmad2 expression were strongly associated with Fig. 3 Disease-free survival curves based on a stratified Cox regression model to compare the breast cancer survival rate among breast cancer patients with different TGF-bRII and pSmad2 expressions earlier age at onset independent of ER status, which supports our findings. In addition, it showed that TGF-bRII expression was associated with smaller tumor size, while high pSmad2 expression was associated with positive axillary node metastasis [34] .
To the best of our knowledge, this study is the largest to evaluate the correlation of TGF-b signaling with clinicopathological factors in both human breast cancer and adjacent normal breast tissue. This study has several notable strengths. The population-based study design and high overall response rate (80 %) minimized potential selection bias. The pathological diagnoses and histological grading were reviewed and confirmed by a centralized laboratory. The stained slides were scored separately by two investigators blinded to clinical data, and all the slides with inconsistent results were re-evaluated jointly to get a consensus score. We used whole tissue sections in this study, which may provide more accurate information than a biopsy [32] [33] [34] .
This study also has some limitations. A major limitation is that the pathological tissue slides were collected from multiple hospitals and stored for about 10 years before staining. Degradation of protein antigenicity may vary despite use of a standard protocol to collect, process, and store tissue sections to maximally preserve tissue antigens. Tissue antigen degradation might have reduced the statistical power of this study. In addition, the followup period of this cohort is relatively short. Our ongoing follow-up with the cohort would overcome this limitation and allow an examination of the long-term associations between TGF-bRII/pSmad2 expression and breast cancer prognosis.
In summary, our findings suggest that increased pSmad2 expression, reduced TGF-bRII expression, and cytoplasmic presence of TGF-bRII may be independent predictors of breast cancer prognosis. These findings provide additional evidence to support the important role of TGF-b signaling in breast cancer prognosis.
